Webinar Date/Time: Wed, Sep 20, 2023 10:00 AM EDT
Discover how patient insurance impacts clinical trial enrollment and explore a game-changing solution that removes financial barriers, ensuring equitable access to standard-of-care therapies. Join us as we unveil the power of CTRx in improving diversity, equity, and inclusion while enhancing patient flexibility and reducing costs for a more inclusive research landscape.
Register Free: https://www.appliedclinicaltrialsonline.com/act/patient-centricity
Event Overview:
This presentation explores the impact of diversity, equity, and inclusion (DEI) and enrollment barriers in the landscape of clinical trials. It highlights the statistics showcasing how delayed enrollment and dropouts can be related to patient insurance issues. The presentation explores a potential solution for overcoming these barriers by removing financial obstacles presented when leveraging patient insurance alone.
The suggested solution focuses on exploring various options to alleviate the financial burden associated with one of the largest and often overlooked expenses associated with clinical trial participation – SoC therapies. Is SoC truly accessible for all? The discussion ultimately concludes that the best solution lies in leveraging CTRx to improve DEI and patient centricity.
CTRx offers multiple benefits, including reduced costs, enhanced patient flexibility, and decreased reliance on sponsor and site resources. By implementing CTRx, clinical trials can effectively remove financial barriers, thereby creating a more equitable and inclusive environment for diverse participants.
Overall, the presentation emphasizes the significance of addressing DEI concerns in clinical trial enrollment and highlights the potential of CTRx as a solution for improving accessibility and inclusivity in the research landscape.
Key Learning Objectives:
Who Should Attend:
Speaker:
Samit Bhatt
Vice President, Clinical Trial Patient Solutions
Myonex
Samit is the Vice President for the Clinical Trial Patient Solutions team at Myonex. He is responsible for the team’s growing global operations in North America, Europe, Australia, and New Zealand. Samit has over 13 years’ experience in the pharmacy and pharmaceutical industry. Experience includes managing successful formulary status and relationship management with payers. Samit has a significant understanding of healthcare contracts and knowledge of medical and pharmacy benefits, including specialized knowledge across different therapeutic areas. Samit holds both a Doctor of Pharmacy degree and a MBA from Drake University.
Register Free: https://www.appliedclinicaltrialsonline.com/act/patient-centricity
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
Tirzepatide Reduces Heart Failure Risk, Improves Physical Function in HFpEF Patients
November 18th 2024The Phase III SUMMIT trial showed that tirzepatide significantly reduces the risk of worsening heart failure events or death from cardiovascular causes, enhances physical function, and leads to weight loss and reduced inflammation in patients with heart failure with preserved ejection fraction.